Remove 2024 Remove Atrial Fibrillation Remove Embolism
article thumbnail

Biosense Webster Begins Enrollment of Pivotal Trial Evaluating the Laminar Left Atrial Appendage Elimination Device?

DAIC

Getty Images milla1cf Tue, 02/27/2024 - 17:24 February 27, 2024 — Biosense Webster, Inc. , Bernard's Heart & Vascular Center , Jonesboro, Arkansas) mark a significant milestone in the pursuit of innovative solutions for non-valvular atrial fibrillation (NVAF) treatment.

article thumbnail

Abstract TP223: Predicting Atrial Fibrillation in Embolic Stroke of Unknown Source

Stroke Journal

Stroke, Volume 55, Issue Suppl_1 , Page ATP223-ATP223, February 1, 2024. Background:A considerable portion of patients with embolic stroke of unknown source(ESUS)are later found to have occult atrial fibrillation (AF).

article thumbnail

Mass screening for atrial fibrillation does not prevent stroke in older adults, research finds

Medical Xpress - Cardiology

Mass screening for atrial fibrillation using ECG together with heart failure biomarker does not prevent ischemic stroke or systemic embolism (blood clot) in older adults aged 75–76 years over 5 years follow-up, according to late breaking research presented in a Hot Line Session at this year's ESC Congress 2024 in London, UK (30 Aug–2 Sept).

article thumbnail

Stroke Prevention in Atrial Fibrillation: Our Current Failures and Required Research

Stroke Journal

Stroke, Volume 55, Issue 1 , Page 214-225, January 1, 2024. Nonvalvular atrial fibrillation is a common rhythm disorder of middle-aged to older adults that can cause ischemic strokes and systemic embolism.

article thumbnail

Study Shows Abelacimab Significantly Reduced Bleeding vs. Standard DOAC

DAIC

Affecting 60 million people worldwide 1 , the prevalence of atrial fibrillation (AFib) is expected to increase by 60% by 2050 due to an aging population and rising cardiometabolic risk factors 2. In addition, the Centers for Disease Control and Prevention (CDC) estimates that more than 12 million Americans will have AFib by 2030 3.

AFIB 52
article thumbnail

CHA2DS2-VASc Score Guides Oral Anticoagulation in Patients With SCAF

American College of Cardiology

The baseline CHA2DS2-VASc score helped to identify patient with subclinical atrial fibrillation (SCAF) in whom the benefit for reducing the risk of stroke and systemic embolism (SE) with an oral anticoagulant (OAC) was greater than the risk of increased major bleeding, according to a subgroup analysis from the ARTESiA study presented at Heart Rhythm (..)

article thumbnail

ENBALV: Edoxaban vs. Warfarin Following Bioprosthetic Valve Surgery in Patients With Non-Valvular AFib

American College of Cardiology

Edoxaban was comparable to warfarin in preventing stroke or systemic embolism and intracardiac thrombus in patients with non-valvular atrial fibrillation (AFib) within three months after bioprosthetic valve surgery, based on preliminary findings from the ENBALV trial presented at AHA 2024.

AFIB 50